Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.

ABSTRACT: The emergence of drug-resistant tuberculosis (TB) is a growing problem worldwide. The lack of safe and effective drugs, together with the frequent development of adverse drug reactions can result in worse outcomes. Therefore, new TB drugs able to bolster the current TB treatment regimen are urgently required. Novel drugs that are effective and safe against Mycobacterium tuberculosis are required to reduce the number of drugs and the duration of treatment in both drug-susceptible TB and multi-drug-resistant (MDR)-TB. This review covers promising novel TB drugs and regimens that are currently under development. Bedaquiline and delamanid are the most promising novel drugs for the treatment of MDR-TB, each having a high efficacy and tolerability. However, the best regimen for achieving

SUBMITTER: Kwon YS 

PROVIDER: S-EPMC5457944 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature